Mutagenesis of p38α MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state

Biochemistry

Volumn 46, Issue 19, 2007, Pages 5687-5696

  Bukhtiyarova, Marina ^a   Karpusas, Michael ^a   Northrop, Katrina ^a   Namboodiri, Haridasan V M ^a   Springman, Eric B ^a  

^a Locus Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAP KINASE STRUCTURE; X-RAY CRYSTAL STRUCTURES;

CRYSTAL STRUCTURE; ENZYME ACTIVITY; MUTAGENESIS; PHOSPHORYLATION; THERMODYNAMIC STABILITY; X RAY ANALYSIS;

STRUCTURAL DYNAMICS;

ACTIVATING TRANSCRIPTION FACTOR 2; AMINO ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MUTANT PROTEIN; PHE169; UNCLASSIFIED DRUG; PHENYLALANINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; HIGH TEMPERATURE; IN VITRO STUDY; MOLECULAR DYNAMICS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN VARIANT; SIMULATION; THERMOSTABILITY; WILD TYPE; X RAY DIFFRACTION; ALLOSTERISM; AMINO ACID SEQUENCE; CHEMISTRY; CRYSTALLIZATION; ESCHERICHIA COLI; GENETICS; HEAT; METABOLISM; PHYSIOLOGY; PROTEIN DENATURATION; PROTEIN MOTIF; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; HEAT; MAP KINASE KINASE 6; MITOGEN-ACTIVATED PROTEIN KINASE 14; MUTAGENESIS, SITE-DIRECTED; PHENYLALANINE; PROTEIN CONFORMATION; PROTEIN DENATURATION;

EID: 34248569419     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0622221     Document Type: Article

References (37)

1. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis, Nature 372, 739-746.
2. Han, J., Lee, J. D., Bibbs, L., and Ulevitch, R. J. (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells, Science 265, 808-811.
3. Herlaar, E., and Brown, Z. (1999) p38α MAPK signaling cascades in inflammatory disease, Mol. Med. Today 5, 439-447.
4. Lee, J. C., Kumar, S., Griswold, D. E., Underwood, D. C., Votta, B. J., and Adams, J. L. (2000) Inhibition of p38α MAP kinase as a therapeutic strategy, Immunopharmacology 47, 185-201.
5. Johnson, L. N., Noble, M. E., and Owen, D. J. (1996) Active and inactive protein kinases: structural basis for regulation, Cell 85, 149-158.
6. Nolen, B., Taylor, S., and Ghosh, G. (2004) Regulation of protein kinases: controlling activity through activation segment conformation, Mol. Cell 15, 661-675.
7. Kannan, N., and Neuwald, A. F. (2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component?, J. Mol. Biol. 351, 956-972.
8. Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., and Kuriyan, J. (2006) A Src-like inactive conformation in the Abl tyrosine kinase domain, PLoS Biol. 4, 753-767.
9. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., and Regan, J. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site, Nat. Struct. Biol. 9, 268-272.
10. Regan, J., Breitfelder, S., Cirillo, P., Gilmore, T., Graham, A. G., Hickey, E., Klaus, B., Madwed, J., Moriak, M., Moss, N., Pargellis, C., Pav, S., Proto, A., Swinamer, A., Tong, L., and Torcellini, C. (2002) Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate, J. Med. Chem. 45, 2994-3008.
11. Mol, C. D., Fabbro, D., and Hosfield, D. J. (2004) Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors, Curr. Opin. Drug Discovery Dev. 7, 639-648.
12. Knight, Z. A., and Shokat, K. M. (2005) Features of selective kinase inhibitors, Chem. Biol. 12, 621-637.
13. Liu, Y., and Gray, N. S. (2006) Rational design of inhibitors that bind to inactive kinase conformations, Nat. Chem. Biol. 2, 358-364.
14. Frembgen-Kesner, T., and Elcock, A. H. (2006) Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase, J. Mol. Biol. 359, 202-214.
15. Vogtherr, M., Saxena, K., Hoelder, S., Grimme, S., Betz, M., Schieborr, U., Pescatore, B., Robin, M., Delarbre, L., Langer, T., Wendt, K. U., and Schwalbe, H. (2006) NMR characterization of kinase p38 dynamics in free and ligand-bound forms, Angew. Chem., Int. Ed. 45, 993-997.
16. Bukhtiyarova, M., Northrop, K., Chai, X., Casper, D., Karpusas, M., and Springman, E. (2004) Improved expression, purification, and crystallization of p38alpha MAP kinase, Protein Expression Purif. 37, 154-161.
17. Kroe, R. R., Regan, J., Proto, A., Peet, G. W., Roy, T., Landro, L. D., Fuschetto, N. G., Pargellis, C. A., and Ingraham, R. H. (2003) Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors, J. Med. Chem. 46, 4669-4675.
18. Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor, Biochemistry 44, 5258-5266.
19. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode, Macromol. Crystallogr. A 276, 307-326.
20. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination, Acta Crystallogr. D. Biol. Crystallogr. 54, 905.
21. Taylor, S. S., and Radzio-Andzelm, E. (1994) Three protein kinase structures define a common motif, Structure 2, 345-355.
22. Sullivan, J. E., Holdgate, G. A., Campbell, D., Timms, D., Gerhardt, S., Breed, J., Breeze, A. L., Bermingham, A., Pauptit, R. A., Norman, R. A., Embrey, K. J., Read, J., VanScyoc, W. S., and Ward, W. H. J. (2005) Prevention of MKK6-dependednt activation by binding to p38α MAP kinase, Biochemistry 44, 16475-16490.
23. Michelotti, E. L., Moffett, K. K., Nguyen, D., Kelly, M. J., Shetty, R., Chai, X., Northrop, K., Namboodiri, V., Campbell, B., Flynn, G. A., Fujimoto, T., Hollinger, F. P., Bukhtiyarova, M., Springman, E. B., and Karpusas, M. (2005) Two classes of p38α MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes, Bioorg. Med. Chem. Lett. 15, 5274-5279.
24. Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Davidson, W., Hopkins, J., Brown, M. L., Pargellis, C. A., and Tong, L. (1997) Crystallization and preliminary crystallographic analysis of recombinant human p38 MAP kinase, Protein Sci. 6, 242-245.
25. Cherry, M., and Williams, D. H. (2004) Recent kinase and kinase inhibitor x-ray structures: mechanisms of inhibition and selectivity insights, Curr. Med. Chem. 11, 663-673.
26. Huse, M., and Kuriyan, J. (2002) The conformational plasticity of protein kinases, Cell 109, 275-282.
27. Morris, A. L., MacArthur, M. W., Hutchinson, E. G., and Thornton, J. M. (1992) Stereochemical quality of protein structure coordinates, Proteins: Struct., Funct., Genet. 12, 345-364.
28. Lovell, S. C., Davis, I. W., Arenall, W. B., III, de Bakker, P. I. W., Word, J. M., Prisant, M. G., Richardson, J. S., and Richardson, D. C. (2003) Structure validation by Ca geometry: φ, ψ and Cβ deviation, Proteins: Struct., Funct., Genet. 50, 437-450.
29. Kuma, Y., Sabio, G., Bain, J., Shapiro, N., Márquez, R., and Cuenda, A. (2005) BIRB 796 inhibits all p38 MAPK isoforms in vitro and in vivo, J. Biol. Chem. 280, 19472-19479.
30. Jauch, R., Jäkel, S., Netter, C., Schreiter, K., Aicher, B., Jäckle, H., and Wahl, M. C. (2005) Crystal Structure of Mnk2 kinase domain reveal an inhibitory conformation and a Zinc binding site, Structure 13, 1559-1568.
31. Bellon, S., Fitzgibbon, M. J., Fox, T., Hsiao, H. M., and Wilson, K. P. (1999) The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation, Structure 7, 1057-1065.
32. Kornev, A. P., Haste, N. M., Taylor, S. S., and Ten Eyck, L. F. (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism, Proc. Nat. Acad. Sci. U.S.A. 103, 17783-17788.
33. Lee, T., Hoofnagle, A. N., Resing, K. A., and Ahn, N. G. (2005) Hydrogen exchange solvent protection by an ATP analogue reveals conformational changes in ERK2 upon activation, J. Mol. Biol. 353, 600-612.
34. Shoichet, S. K., Baase, W. A., Kuroki, R., and Matthews, B. W. (1995) A relationship between protein stability and protein function, Proc Natl. Acad. Sci. U.S.A. 92, 452-456.
35. Hubbard, S. R., Mohammadi, M., and Schlessinger, J. (1998) Autoregulatory mechanisms in protein-tyrosine kinases, J. Biol. Chem. 273, 11987-11990.
36. Cheetham, G. M. T. (2004) Novel protein kinases and molecular mechanisms of autoinhibition, Curr. Opin. Struct. Biol. 14, 700-705.
37. Gay, L. M., Ng, H.-L., and Alber, T. (2006) A conserved dimer and global conformational changes in the structure of apo-PknE Ser/Thr protein kinase from Mycobacterium tuberculosis, J. Mol. Biol. 360, 409-420.